CD272, also known as B and T lymphocyte attenuator (BTLA), is an Ig superfamily co-inhitory receptor with structural similarity to programmed cell death 1 (PD-1) and CTLA-4.  BTLA is expressed on B cells, T cells, macrophages, dendritic cells, NKT cells, and NK cells. Engagement of BTLA by its ligand herpes virus entry mediator (HVEM) is critical for negatively regulating immune response.  The absence of BTLA with HVEM inhibitory interactions leads to increased experimental autoimmune encephalomyelitis severity, enhanced rejection of partially mismatched allografts, an increased CD8⁺ memory T cell population, increased severity of colitis, and reduced effectiveness of T regulatory cells.  BTLA plays an important role in the induction of peripheral tolerance of both CD4⁺ and CD8⁺ T cells in vivo.  Tolerant T cells have significantly higher expression of BTLA compared with effectors and naïve T cells.  BTLA may cooperate with CTLA-4 and PD-1 to control T cell tolerance and autoimmunity.  It was reported that BTLA may regulate T cell function by binding to B7-H4, but further studies are needed to confirm.  The existence of three distinct BTLA alleles has been reported.

PRODUCT DETAILS

Clone: 6A6

Antibody Type: Monoclonal

Reactivity: Mouse

Format: PE

Host: Armenian Hamster

Isotype: IgG

Applications: FC - Quality tested

Regulatory Status: RUO

Data Sheets: TDS | SDS

Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.